Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor-21 (FGF-21) plays a critical role in metabolic-disorder related hypertension through the afferent loop of baroreflex.
|
31626954 |
2020 |
Metabolic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We provide a comprehensive overview on human circulating FGF21 levels under normal physiology and metabolic disease.
|
31108554 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 is a hormone that mediates a number of beneficial effects relevant to metabolic disorders and their associated complications.
|
31511499 |
2019 |
Metabolic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated levels of FGF21 in serum during the early stages of various metabolic diseases are considered a compensatory response by the organism.
|
31175491 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Among those browning agents reported recently, FGF21 play as a quite promising candidate for treating obesity for its obvious enhancement of thermogenic capacity in adipocyte and significant improvement of metabolic disorders in both mice and human.
|
30496126 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma FGF-21 and GDF-15 are elevated in different inherited metabolic diseases and are not diagnostic for mitochondrial disorders.
|
31260105 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21) is closely linked with metabolic disorders including diabetes.
|
31205953 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the role of FGF21 in macronutrient intake and metabolic disease, particularly in pediatric population, still needs further clarification.
|
31323006 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies showed that FGF21 ameliorated and prevented the development of metabolic disorders, such as obesity and diabetes mellitus.
|
30991048 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The data demonstrate an important AHR-FGF21 regulatory axis that influences adipose biology and may represent a "druggable" therapeutic target for obesity and its related metabolic disorders.
|
30813227 |
2019 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recombinant FGF21 analogs are under wide ranging investigations as a potential therapeutic agent for Type 2 diabetes, as well as other metabolic disorders.
|
29239666 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity.
|
29883971 |
2018 |
Metabolic Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Betatrophin and fibroblast growth factor-21 (FGF-21), which are recently discovered members of hepatokine/adipokine family, have been proposed to be associated with some metabolic disorders in which insulin resistance plays a major role.
|
29363048 |
2018 |
Metabolic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Together, these results demonstrate that FGF21 reduces the increased expression of a subset of genes in the liver in response to ER stress and may correct metabolic disorders caused by ER stress.
|
29962431 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The ELP fusion partner massively streamlines production and purification of FGF21, while providing a controlled release method for delivery that reduces the frequency of injection, thereby enhancing the pharmacological properties of FGF21 as a protein drug to treat metabolic disease.
|
29551712 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum concentrations of FGF-21 were correlated with the concentrations of total cholesterol, triglycerides, and HbA1c, which are important factors of metabolic disorders in females, suggesting that metabolic disorders in female smokers may be more serious than that in male smokers.
|
29132901 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A molecular pathway involving the carbohydrate responsive element-binding protein (ChREBP) and the metabolic hormone fibroblast growth factor 21 (FGF21) may influence sugar metabolism and, thereby, contribute to fructose-induced metabolic disease.
|
29098321 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review examines the numerous functions of FGF21 and highlights the therapeutic potential of FGF21-targeted pathways for treating metabolic disease.
|
29727594 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 has recently emerged as a promising drug candidate for metabolic diseases.
|
29859019 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, 39F7 offers promising therapeutic potential in the axis of FGF21 signaling as an antibody therapy alternative to FGF21 analogs for treatment of metabolic diseases.
|
30068552 |
2018 |
Metabolic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PubMed and EMBASE were searched until 5th September 2017 for studies that evaluated the roles of FGF21 levels in cardio-metabolic disorders.
|
29410351 |
2018 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we critically appraise current advances in understanding the physiological actions of FGF21 and its role as a biomarker of various metabolic diseases, especially type 2 diabetes mellitus.
|
28559437 |
2017 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, while an association between increased circulating FGF21 and metabolic disorders has been reported in adults, paediatric-specific data are lacking.
|
28139438 |
2017 |
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A scalable, viable process was developed for the Fibroblast Growth Factor 21 (FGF21) protein-antibody conjugate, CVX-343, an extended half-life therapeutic for the treatment of metabolic disease.
|
28948603 |
2017 |
Metabolic Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further investigations to dissect the relationship between GCKR and FGF21, with respect to the risk of metabolic diseases, are warranted.
|
28385800 |
2017 |